Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_assertion type Assertion NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_head.
- NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_assertion description "[Chronic treatment with AVE3085 did not alter arterial BP or severe hyperglycaemia, but did lead to significantly increased production of eNOS (+95%), cGMP (+128%) and VASP phosphorylation (+65%) as well as to improved vascular function (+36%) associated with reduced production of ICAM-1 (-36%) and VCAM-1 (-58%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_provenance.
- NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_assertion evidence source_evidence_literature NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_provenance.
- NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_assertion SIO_000772 18825362 NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_provenance.
- NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_assertion wasDerivedFrom befree-20140225 NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_provenance.
- NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_assertion wasGeneratedBy ECO_0000203 NP631896.RABIAQ9WQf1CrORc-6Hg_Xw3C-fqxBNhnyatnLS3poIFo130_provenance.